![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 16, 2024 8:21:36 AM
ROCKVILLE, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will participate in a fireside chat at the B. Riley Securities Oncology Conference to be held virtually on Thursday, January 18, 2024 at 9:30 a.m. ET.
To register for this event, please reach out to your B. Riley Securities sale representative. The replay of the presentation will be accessible in the “Investors” section of the company’s website, https://www.therivabio.com, under “Events.”
About Theriva Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at https://www.therivabio.com.
For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
mailto://ccalabrese@lifesciadvisors.com
917-680-5608
Source: Theriva Biologics, Inc.
![Bullish](/static/images/ih2-bull.png)
Recent TOVX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:20:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 11:30:14 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:10:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:05:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:10:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:07:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:01:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:00:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:15:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 11:10:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 10:05:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 10:06:35 AM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 08/16/2023 09:24:26 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2023 01:53:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/14/2023 09:11:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:30:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 01:03:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 12:10:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 01:22:02 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM